Massie MJ, Holland JC (1990) Depression and the cancer patient. J Clin Psychiatry 51(Suppl):12–19
Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 18(4):893–903. https://doi.org/10.1200/JCO.2000.18.4.893
Article CAS PubMed Google Scholar
Charlesworth L, Fegan C, Ashmore R (2023) How does severe mental illness impact on cancer outcomes in individuals with severe mental illness and cancer? A scoping review of the literature. J Med Imaging Radiat Sci 54(2S):S104–S114. https://doi.org/10.1016/j.jmir.2023.01.007
Sellick SJ, Crooks PA (1999) Depression and cancer: an appraisal of the literature for prevalence, detection, and practice guideline development for psychological interventions. Psycho-Oncol 8(4):315–333. https://doi.org/10.1002/(SICI)1099-1611(199907)8:4<315::AID-PON312>3.0.CO;2-R
Singer S, Das-Munshi J, Brähler E (2010) Prevalence of mental health conditions in cancer patients in acute care–a meta-analysis. Ann Oncol 21(5):925–930. https://doi.org/10.1093/annonc/mdq097
Article CAS PubMed Google Scholar
Chochinov HM, Wilson KG, Enns M, Lander S (1994) Prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgments. Am J Psychiatry 151(4):537–540. https://doi.org/10.1176/ajp.151.4.537
Article CAS PubMed Google Scholar
Massie MJ (2004) Prevalence of depression in patients with cancer. JNCI Monogr 2004(32):57–71
Bortolato B, Hyphantis TN, Valpione S, Perini G, Maes M, Morris G, Kubera M, Köhler CA, Fernandes BS, Stubbs B, Pavlidis N, Carvalho AF (2017) Depression in cancer: the many biobehavioral pathways driving tumor progression. Cancer Treat Rev 52:58–70. https://doi.org/10.1016/j.ctrv.2016.11.004
Quante A, Schulz K, Fissler M (2020) Psychiatric comorbidities in cancer patients: acute interventions by the psychiatric consultation liaison service. Wien Med Wochenschr 170(13–14):348–356. https://doi.org/10.1007/s10354-020-00739-0
Arrieta O, Angulo LP, Núñez-Valencia C, Dorantes-Gallareta Y, Macedo EO, Martínez-López D, Alvarado S, Corona-Cruz JF, Oñate-Ocaña LF (2013) Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol 20(6):1941–1948. https://doi.org/10.1245/s10434-012-2793-5
Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A (2000) Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet (London, England) 356(9238):1326–1327. https://doi.org/10.1016/S0140-6736(00)02821-X
Article CAS PubMed Google Scholar
Fitzgerald P, Lo C, Li M, Gagliese L, Zimmermann C, Rodin G (2015) The relationship between depression and physical symptom burden in advanced cancer. BMJ Support Palliat Care 5(4):381–388
Mausbach BT, Schwab RB, Irwin SA (2015) Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 152(2):239–246. https://doi.org/10.1007/s10549-015-3471-7
Article CAS PubMed PubMed Central Google Scholar
Prieto JM, Blanch J, Atala J, Carreras E, Rovira M, Cirera E, Gastó C (2002) Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol 20(7):1907–1917. https://doi.org/10.1200/JCO.2002.07.101
Pederson JL, Warkentin LM, Majumdar SR, McAlister FA (2016) Depressive symptoms are associated with higher rates of readmission or mortality after medical hospitalization: a systematic review and meta-analysis. J Hosp Med 11(5):373–380. https://doi.org/10.1002/jhm.2547
Iglay K, Santorelli ML, Hirshfield KM, Williams JM, Rhoads GG, Lin Y, Demissie K (2017) Impact of preexisting mental illness on all-cause and breast cancer-specific mortality in elderly patients with breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35(36):4012–4018. https://doi.org/10.1200/JCO.2017.73.4947
Grassi L, McFarland D, Riba M (2023) The risk and the course of cancer among people with severe mental illness. Clin Pract Epidemiol Ment Health 19(Suppl-1):e174501792301032. https://doi.org/10.2174/17450179-v17-e211208-2021-HT2-1910-8
Article PubMed PubMed Central Google Scholar
Oechsle K, Ullrich A, Marx G, Benze G, Heine J, Dickel LM, Zhang Y, Wowretzko F, Wendt KN, Nauck F, Bokemeyer C, Bergelt C (2019) Psychological burden in family caregivers of patients with advanced cancer at initiation of specialist inpatient palliative care. BMC Palliat Care 18(1):102. https://doi.org/10.1186/s12904-019-0469-7
Article PubMed PubMed Central Google Scholar
Caruso R, Grassi L, Nanni MG, Riba M (2013) Psychopharmacology in psycho-oncology. Curr Psychiatry Rep 15(9):393. https://doi.org/10.1007/s11920-013-0393-0
Cassileth BR (2014) Psychiatric benefits of integrative therapies in patients with cancer. Int Rev Psychiatry 26(1):114–127. https://doi.org/10.3109/09540261.2013.869436
Grassi L, Riba M (2020) Cancer and severe mental illness: bi-directional problems and potential solutions. Psycho-Oncol 29(10):1445–1451. https://doi.org/10.1002/pon.5415
Vita G, Compri B, Matcham F, Barbui C, Ostuzzi G (2023) Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev 3(3):CD011006. https://doi.org/10.1002/14651858.CD011006
Desmarais JE, Looper KJ (2009) Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 70(12):1688–1697. https://doi.org/10.4088/JCP.08r04856blu
Article CAS PubMed Google Scholar
Yap KY, Tay WL, Chui WK, Chan A (2011) Clinically relevant drug interactions between anticancer drugs and psychotropic agents. Eur J Cancer Care 20(1):6–32. https://doi.org/10.1111/j.1365-2354.2009.01113.x
Daignault C, Sauer HE, Lindsay H, Alonzo A, Foster J (2022) Investigating potential drug-drug interactions in pediatric and adolescent patients receiving chemotherapy. J Oncol Pharm Pract 28(4):904–909. https://doi.org/10.1177/10781552221079786
Chan A, Ng TR, Yap KY (2012) Clinically-relevant anticancer-antidepressant drug interactions. Expert Opin Drug Metab Toxicol 8(2):173–199. https://doi.org/10.1517/17425255.2012.659840
Article CAS PubMed Google Scholar
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71
Article PubMed PubMed Central Google Scholar
Albayrak A, Erbay B, Kayıkçıoğlu E (2024) Assessment of polypharmacy, potentially inappropriate medications, and drug-drug interactions in older patients with cancer. J Oncol Pharm Pract. https://doi.org/10.1177/10781552241255140
Kuhn, K. H., Oliveira, M. R. F., Ribas, M. R., Zimmermann, P. R., & Silva, T. M. (2021). Use of antidepressants and potential drug interactions in cancer patients treated at a hospital in Southern Brazil. Revista de Epidemiologia e Controle de Infecção, 11(1). https://doi.org/10.17058/reci.v1i1.14587
Wedret JJ, Tu TG, Paul D, Rousseau C, Bonta A, Bota RG (2019) Interactions between antidepressants, sleep aids and selected breast cancer therapy. Ment Illn 11(1):8115. https://doi.org/10.4081/mi.2019.8115
Article PubMed PubMed Central Google Scholar
Sanjida S, Mulvogue K, Shaw J, Couper J, Kissane D, Pearson SA, Price MA, Janda M (2018) What type and dose of antidepressants are cancer and non-cancer inpatients being prescribed? A retrospective case-control study at an Australian tertiary hospital. Support Care Cancer 26(2):625–634. https://doi.org/10.1007/s00520-017-3876-4
Reinert CdeA, Ribas MR, Zimmermann PR (2015) Drug interactions between antineoplastic and antidepressant agents: analysis of patients seen at an oncology clinic at a general hospital. Trends Psychiatry Psychother 37(2):87–93. https://doi.org/10.1590/2237-6089-2015-0003
Comments (0)